Current Medical Research and Opinion · 2020 · 10 citations · 16 references
PharmacyInternal MedicinePharmacologyDiabetologyPharmaceutical RegulationPharmacovigilanceBiosimilar RegulationDiabetes MellitusDrug Safety MonitoringGlycemic ControlPost-marketing Safety SurveillancePostmarketing SurveillanceBiosimilar UseLong-term Safety Follow-upPost-market Drug Safety AnalysisPost-market Safety MonitoringPost-marketing Drug Safety SurveillancePost-marketing SurveillancePost-marketing Surveillance AnalysisReference Product Substitution
Objective To evaluate the long-term safety and effectiveness of biosimilar insulin glargine (GLY) in real-world clinical practice.Methods This prospective, non-interventional, multicenter, observational, post-marketing safety study (PMSS) enrolled Japanese patients with type 1 or 2 diabetes mellitus (T1DM or T2DM) starting GLY therapy, and was required by Japanese Pharmaceutical Affairs Law mandating post-marketing safety surveillance to acquire safety and effectiveness data of biosimilar products. Data collected from the 12-month observation included patient characteristics, adverse events, and blood glucose control.Results The study enrolled 141 patients with T1DM and 1104 patients with T2DM. Pre-study insulin was used by 94.1% of patients with T1DM and 75.0% with T2DM. 65.4% of patients with T1DM and 64.3% with T2DM switched from the reference product (GLY-switched), while 25.0% with T2DM were insulin-naive. Adverse events were reported by 5.7% and 8.5% in T1DM and T2DM, respectively. Similar incidences were reported in GLY-switched. Adverse events were reported by 10.7% in insulin-naive T2DM. Baseline mean hypoglycemic events/month were 1.8 and 0.1 in T1DM and T2DM, respectively: the mean change from baseline (CFB) was –1.2 (p = .066) and 0.0 (p = .915), respectively. Baseline mean HbA1c was 8.4% and 8.7% in T1DM and T2DM, respectively; the mean CFB was –0.5% (p < .001) and –0.9% (p < .001), respectively, and –1.5% (p < .001) in insulin-naive T2DM.Conclusions This first long-term Japanese PMSS of GLY demonstrated adverse events, hypoglycemia, and glycemic control consistent with the known GLY profile for T1DM and T2DM patients, in routine clinical practice.
16
Matthew C. Riddle, Geremia B. Bolli, M. Ziemen et al. · Diabetes Care · 2014 · 360 citations
Hannele Yki‐Järvinen, Richard M. Bergenstal, M. Ziemen et al. · Diabetes Care · 2014 · 274 citations
Japanese Clinical Practice Guideline for Diabetes 2016
Masakazu Haneda, Mitsuhiko Noda, Hideki Origasa et al. · Journal of Diabetes Investigation · 2018 · 183 citations · Full text
Julio Rosenstock, Priscilla Hollander, Anuj Bhargava et al. · Diabetes Obesity and Metabolism · 2015 · 109 citations · Full text